Shin Poong Pharmaceuticals expects to be a high-ranked Korean drug maker.
In the Phase III clinical trial, PYRAMAX has shown great promise as an effective weapon against malaria. And it will be introduced in the market sooner or later.
PYRAMAX(pyronaridine-artesunate) is a new combination antimalarial medicine that was jointly developed by the Tropical Diseases Research Programme(TDR), the Medicines for Malaria Venture(MMV) and Shin Poong Pharm Co., Ltd.(Shin Poong).
Shin Poong's new EU GMP-compliant facility was built in Kyeongki-do last year to ensure that manufacturing capacity for each formulation can meet the market demands for this promising new artemisinin-based combination treatment.
Shin Poong is going to apply to FDA and EMEA for new drug permission in the second half of 2009.
One official of Shin Poong said, "Once released in the world market, PYRAMAX is likely to record 100 billion won in sales as one unit. And it will give us a good opportunity to jump to a high-ranked Korean drug maker." <헬스코리아뉴스>
